People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...

Eli Lilly & Co. and Novo Nordisk A/S are competing for drug contracts in the aftermath of drug price scrutiny. Novo has managed to secure a contract with CVS, beating out its competitor. Other news is ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Becky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures ...

CVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to ...

Eli Lilly (LLY) stock dips as CVS Health (CVS) limits access to its weight loss drug Zepbound in favor of Novo Nordisk's (NVO ...